NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Imperagen

Imperagen

Private
ManchesterHealthcare & Life Scienceshttps://imperagen.com/

Last Round

Seed

May 21, 2026

Total Funding Raised

$17.69M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Imperagen is a biotechnology company that provides a digital enzyme evolution platform to accelerate enzyme engineering for the pharmaceutical and chemical industries.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Smart Manufacturing

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

enzyme engineeringbiocatalyststechbioprotein designai-driven biologyautomated wet labbiotechnologysynthetic biologyin-silico designbiocatalysiscomputational biologydrug discoveryindustrial biotechlab automationprotein engineering

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Imperagen Comps

Public and private peers based on sector, stage, and business model.

Imperagen comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Imperagen Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMay 21, 2026
SeedMay 21, 2024
GrantMar 14, 2024
SeedAug 2, 2022

Key People

Founding team and executive leadership

Andrew A.

Founder And CIO

Founding Team

Tim Eyes

Co-Founder Chief Product Officer CPO

Founding Team

Guy Levy-Yurista

Chief Executive Officer

Executive Team

Rob Wilson

Chief Operating Officer

Executive Team

Imperagen Investors

Notable investors and investment history

Imperagen investors
InvestorRounds
IQ CapitalSeed
Innovate UKGrant
Northern GritstoneSeed
PXN VenturesSeed
PXN GroupSeed
PXN VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 21, 2026

    $5M round led by PXN Group

  • Jan 21, 2026

    Grew 20% QoQ from 15 to 18 employees.

Imperagen Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Imperagen Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Imperagen's valuation, stock price, and market status.

Firmographic Details

HeadquartersManchester
Employee Range17
Year Founded2021
Last FundingMay 21, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.